

Sang-Hee Cho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6221731/publications.pdf>

Version: 2024-02-01

39
papers

1,133
citations

623734

14
h-index

434195

31
g-index

40
all docs

40
docs citations

40
times ranked

2382
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer. <i>International Journal of Cancer</i> , 2022, 150, 2038-2045. | 5.1 | 19 |
| 2 | Geriatric functional assessment for decision-making on adjuvant chemotherapy in older colon cancer patients. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 660-672. | 1.7 | 1 |
| 3 | Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). <i>Gastric Cancer</i> , 2021, 24, 156-167. | 5.3 | 29 |
| 4 | Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> , 2021, 160, 1164-1178.e6. | 1.3 | 36 |
| 5 | Association between ALDH2 polymorphism and esophageal cancer risk in South Koreans: a case-control study. <i>BMC Cancer</i> , 2021, 21, 254. | 2.6 | 8 |
| 6 | Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma. <i>Processes</i> , 2021, 9, 792. | 2.8 | 1 |
| 7 | Association between ALDH2 and ADH1B Polymorphisms and the Risk for Colorectal Cancer in Koreans. <i>Cancer Research and Treatment</i> , 2021, 53, 754-762. | 3.0 | 14 |
| 8 | Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. <i>Cancer Science</i> , 2021, 112, 4669-4678. | 3.9 | 8 |
| 9 | PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2903-2913. | 1.6 | 154 |
| 10 | Long term complications and prognostic factors in locally advanced nasopharyngeal carcinoma treated with docetaxel, cisplatin, 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy. <i>Medicine (United States)</i> , 2020, 99, e23173. | 1.0 | 5 |
| 11 | A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases. <i>Clinical Colorectal Cancer</i> , 2020, 19, e140-e150. | 2.3 | 9 |
| 12 | Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer. <i>Cancer Science</i> , 2020, 111, 3268-3278. | 3.9 | 15 |
| 13 | Association between ALDH2 Polymorphism and Gastric Cancer Risk in a Korean Population. <i>Journal of Korean Medical Science</i> , 2020, 35, e148. | 2.5 | 4 |
| 14 | Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial. <i>Cancer Research and Treatment</i> , 2020, 52, 246-253. | 3.0 | 21 |
| 15 | Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2157-2166. | 2.5 | 14 |
| 16 | IL-12 Enhances Immune Response by Modulation of Myeloid Derived Suppressor Cells in Tumor Microenvironment. <i>Chonnam Medical Journal</i> , 2019, 55, 31. | 0.9 | 35 |
| 17 | Discovery of common and rare genetic risk variants for colorectal cancer. <i>Nature Genetics</i> , 2019, 51, 76-87. | 21.4 | 377 |
| 18 | The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 165-177. | 1.7 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 300-312. | 3.0 | 48 |
| 20 | Exosomal miR-181b-5p Downregulation in Ascites Serves as a Potential Diagnostic Biomarker for Gastric Cancer-associated Malignant Ascites. <i>Journal of Gastric Cancer</i> , 2019, 19, 301. | 2.5 | 24 |
| 21 | Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 660-671. | 10.7 | 107 |
| 22 | TAp73 inhibits cell invasion and migration by directly activating KAI1 expression in colorectal carcinoma. <i>Cancer Letters</i> , 2018, 415, 106-116. | 7.2 | 18 |
| 23 | Epithelial mesenchymal transition in an advanced BRAF mutation type colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 693-693. | 1.6 | 0 |
| 24 | Lymph node ratio as a clinical determinant for selecting adjuvant chemotherapy regimen in curative D2 resected gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4034-4034. | 1.6 | 0 |
| 25 | Long-term outcomes after induction chemotherapy with docetaxel, cisplatin and 5-FU (TPF) followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18008-e18008. | 1.6 | 0 |
| 26 | Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer. <i>Oncologist</i> , 2017, 22, 293-303. | 3.7 | 5 |
| 27 | The use of anticoagulants in terminal cancer patients admitted in hospice center.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21503-e21503. | 1.6 | 1 |
| 28 | The optimal chemotherapeutic regimen in D2-resected locally advanced gastric cancer: a propensity score-matched analysis. <i>Oncotarget</i> , 2017, 8, 66559-66568. | 1.8 | 3 |
| 29 | FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition. <i>Cancer Research and Treatment</i> , 2017, 49, 766-777. | 3.0 | 12 |
| 30 | Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) vs IV paclitaxel in patients with gastric cancer after failure of first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4016-4016. | 1.6 | 3 |
| 31 | Follow-up data from a phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1 based chemoradiotherapy for advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 116-116. | 1.6 | 0 |
| 32 | The prognostic role of PD L1 expression according to MSI status in stage III colon cancer after curative resection.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15128-e15128. | 1.6 | 0 |
| 33 | A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A Korean South West Oncology Group Study. <i>Oncologist</i> , 2015, 20, 1432-1439. | 3.7 | 21 |
| 34 | Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 541-6. | 1.3 | 28 |
| 35 | Prognostic role of PD-L1 polymorphism according to MSI in colon cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e14578-e14578. | 1.6 | 0 |
| 36 | Prospective multicenter study evaluating adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients: a KSWOG (Korean South West Oncology Group) study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9605-9605. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Different protein expression associated with chemotherapy response in oropharyngeal cancer according to HPV status. <i>BMC Cancer</i> , 2014, 14, 824. | 2.6 | 13 |
| 38 | Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 589-595. | 2.3 | 66 |
| 39 | Polymyositis and myocarditis after donor lymphocyte infusion. <i>International Journal of Hematology</i> , 2009, 90, 113-116. | 1.6 | 14 |